Skip to main content

Closed

SLS: SELLAS Life Sciences Group, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth+0.0% / yr

Operating margin0.0%

ROIC-29.1%

Financially safe

Stretched

Debt / equity0.01×

Interest coverage0.0×

Current ratio17.22×

SELLAS Life Sciences Group, Inc.

SLSNASDAQ·USD·Closed

SELLAS Life Sciences Group, Inc.

SLSNASDAQ·USD·Closed

$10.01

−2.72%

$10.01

−$0.28 (2.72%)

52W Range

59thpctl

Volume

0.52×avg

Mkt Cap

1.86BUSD

P/E

-43.8TTM

Div Yield

–ann

52W Range

59thpctl

Volume

0.52×avg

Market Cap

1.86BUSD

P/E Ratio

-43.8TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings